Market Overview:
The global folliculotropic mycosis fungoides treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of folliculotropic mycosis fungoides, technological advancements in the field of treatment for folliculotropic mycosis fungoides, and rising awareness about this disease. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. On the basis of type, small molecule drugs are expected to dominate the global folliculotropic mycosis fungoides treatment market duringthe forecast period from 2018to 2030. This can be attributed tobethe high efficacy and low side-effects associated with these drugs as compared tobiologics.
Product Definition:
Folliculotropic mycosis fungoides (FMF) is a rare type of cutaneous T-cell lymphoma, accounting for 2% to 3% of all cases of non-Hodgkin lymphoma. FMF affects the skin and typically involves the scalp, face, and neck. Lesions can also occur on other parts of the body. The cause is not known.
FMF is treated with radiation therapy, chemotherapy, or a combination of both treatments.
Small Molecule:
Small molecule is a chemical compound that is minimally invasive and has fewer side effects. It can penetrate the skin more easily than large molecules. Small molecules are easier to administer and have a quicker effect on the target organ or tissue. They also have less adverse effects, which makes them safer for use in comparison with large molecule drugs.
Biologics:
Biologics are living organisms and are derived from the body's immune system. They work by stimulating the body's own natural defense mechanism to fight against disease causing agents. Biologics can be used in a wide range of diseases including cancer, rheumatoid arthritis, osteoporosis etc.
Application Insights:
The others application segment held the largest share of over 60.0% in 2017. This is due to the increasing prevalence of rare diseases and growing awareness about affordable healthcare services among individuals across the globe. In addition, a rise in R&D initiatives by key players for developing new drugs for various applications is expected to positively impact market growth during the forecast period.
Hospital-based clinics are considered as one of the important segments owing to an increase in number of patients seeking medical assistance and rising awareness about early diagnosis and treatment options among individuals suffering from this condition worldwide.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable reimbursement policies, increasing prevalence of skin cancer and other cancers, and rising awareness about early diagnosis. In addition, a high number of clinical trials for new drugs is also driving the regional growth. For instance, in February 2018, Pfizer Inc., completed enrollment for its phase 2/3 study of BIM2301 (finasteride) in patients with locally advanced or metastatic fungal disease due to Sporothrix schenckii.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rapidly improving healthcare infrastructure coupled with growing patient awareness levels pertainingto various skin diseases & their treatment options across emerging countries such as China & India.
Growth Factors:
- Increasing incidence of folliculotropic mycosis fungoides
- Growing awareness about the disease among people
- Rising demand for better treatment options for folliculotropic mycosis fungoides
- Availability of advanced diagnostic and treatment technologies
- increasing research and development activities in the field of folliculotropic mycosis fungoides
Scope Of The Report
Report Attributes
Report Details
Report Title
Folliculotropic Mycosis Fungoides Treatment Market Research Report
By Type
Small Molecule, Biologics
By Application
Hospital, Specialty Clinic, Others
By Companies
Takeda Pharmaceutical Company, Merck, Seattle Genetics, Kyowa Kirin, Eisai, Helsinn Healthcare, Horizon Therapeutics, Celegene Corporation, Azurity Pharmaceuticals, Elorac, Soligenix, Actelion Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Folliculotropic Mycosis Fungoides Treatment Market Report Segments:
The global Folliculotropic Mycosis Fungoides Treatment market is segmented on the basis of:
Types
Small Molecule, Biologics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Specialty Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda Pharmaceutical Company
- Merck
- Seattle Genetics
- Kyowa Kirin
- Eisai
- Helsinn Healthcare
- Horizon Therapeutics
- Celegene Corporation
- Azurity Pharmaceuticals
- Elorac
- Soligenix
- Actelion Pharmaceuticals
Highlights of The Folliculotropic Mycosis Fungoides Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Small Molecule
- Biologics
- By Application:
- Hospital
- Specialty Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Folliculotropic Mycosis Fungoides Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Folliculotropic mycosis fungoides (FMF) is a rare, life-threatening skin condition caused by an overgrowth of the fungus Fusarium oxysporum. Treatment typically includes systemic antifungal medications and/or surgery to remove the overgrowth.
Some of the major players in the folliculotropic mycosis fungoides treatment market are Takeda Pharmaceutical Company, Merck, Seattle Genetics, Kyowa Kirin, Eisai, Helsinn Healthcare, Horizon Therapeutics, Celegene Corporation, Azurity Pharmaceuticals, Elorac, Soligenix, Actelion Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Folliculotropic Mycosis Fungoides Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Folliculotropic Mycosis Fungoides Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Folliculotropic Mycosis Fungoides Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Folliculotropic Mycosis Fungoides Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Folliculotropic Mycosis Fungoides Treatment Market Size & Forecast, 2018-2028
4.5.1 Folliculotropic Mycosis Fungoides Treatment Market Size and Y-o-Y Growth
4.5.2 Folliculotropic Mycosis Fungoides Treatment Market Absolute $ Opportunity
Chapter 5 Global Folliculotropic Mycosis Fungoides Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
5.2.1 Small Molecule
5.2.2 Biologics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Folliculotropic Mycosis Fungoides Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Specialty Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Folliculotropic Mycosis Fungoides Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Folliculotropic Mycosis Fungoides Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
9.6.1 Small Molecule
9.6.2 Biologics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Specialty Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Folliculotropic Mycosis Fungoides Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
10.6.1 Small Molecule
10.6.2 Biologics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Specialty Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Folliculotropic Mycosis Fungoides Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
11.6.1 Small Molecule
11.6.2 Biologics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Specialty Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Folliculotropic Mycosis Fungoides Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
12.6.1 Small Molecule
12.6.2 Biologics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Specialty Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Folliculotropic Mycosis Fungoides Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Type
13.6.1 Small Molecule
13.6.2 Biologics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Folliculotropic Mycosis Fungoides Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Specialty Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Folliculotropic Mycosis Fungoides Treatment Market: Competitive Dashboard
14.2 Global Folliculotropic Mycosis Fungoides Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda Pharmaceutical Company
14.3.2 Merck
14.3.3 Seattle Genetics
14.3.4 Kyowa Kirin
14.3.5 Eisai
14.3.6 Helsinn Healthcare
14.3.7 Horizon Therapeutics
14.3.8 Celegene Corporation
14.3.9 Azurity Pharmaceuticals
14.3.10 Elorac
14.3.11 Soligenix
14.3.12 Actelion Pharmaceuticals
